Cited by 196Lipid metabolism and disordersLipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

The DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.

The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans

Open access

Borén, Jan, Packard, Chris J., Taskinen, Marja-Riitta·2020·Frontiers in Endocrinology

DOI 10.3389/fendo.2020.00474PMC PMC7399058

Open this paper in CoChat — free account Open PDF

Abstract

Cardiovascular disease (CVD) is the leading cause of death globally. It is well established based on evidence accrued during the last three decades that high plasma concentrations of cholesterol-rich atherogenic lipoproteins are causatively linked to CVD, and that lowering these reduces atherosclerotic cardiovascular events in humans.1-9 Historically, most attention has been on low-density lipoproteins (LDL) since these are the most abundant atherogenic lipoproteins in the circulation, and thus the main carrier of cholesterol into the artery wall. However, with the rise of obesity and insulin resistance in many populations, there is increasing interest in the role of triglyceride-rich lipoproteins (TRLs) and their metabolic remnants, with accumulating evidence showing they too are causatively linked to CVD. Plasma triglyceride, measured either in the fasting or non-fasting state, is a useful index of the abundance of TRLs and recent research into the biology and genetics of triglyceride heritability has provided new insight into the causal relationship of TRLs with CVD. Of the genetic factors known to influence plasma triglyceride levels variation in APOC3 - the gene for apolipoprotein (apo) C-III - has emerged as being particularly important as a regulator of triglyceride transport and a novel therapeutic target to reduce dyslipidaemia and CVD risk.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.3389/fendo.2020.00474

Cites

150 of 150 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
Chapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A. L., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr112 · Cited by 1,227
Self-citation
Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
The TG and HDL Working Group of the Exome Sequencing Project, N. H. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1307095 · Cited by 1,071
Subendothelial retention of atherogenic lipoproteins in early atherosclerosis
Skålén, K., Gustafsson, M., Rydberg, E. K., Hultén, L. M., Wiklund, O., Innerarity, T. L., & Borén, J. (2002) · Nature · doi:10.1038/nature00804 · Cited by 1,019 · cited 1×
“This is mediated by ionic interactions between positively charged domains in apoB100 (74), and negatively charged artery wall proteoglycans (75).”
BackgroundSelf-citation
Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Jørgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308027 · Cited by 919
RNA-Targeted Therapeutics
Crooke, S. T., Witztum, J. L., Bennett, C. F., & Baker, B. F. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.004 · Cited by 841
Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome
Adiels, M., Olofsson, S.-O., Taskinen, M.-R., & Borén, J. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.160192 · Cited by 820
Self-citation
GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics
Springer, A. D., & Dowdy, S. F. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0736 · Cited by 711 · cited 1×
“Development of novel technologies including ASOs, siRNAs and monoclonal antibodies (137, 138), as well as improved targeting methods (139, 140), including use of N-acetyl galactosamine-conjugated (GalNAc) adducts (i.”
Background
Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease
Ference, B. A., Kastelein, J. J. P., Ray, K. K., Ginsberg, H. N., Chapman, M. J., Packard, C. J., Laufs, U., Oliver-Williams, C., Wood, A. M., Butterworth, A. S., et al. (2019) · JAMA · doi:10.1001/jama.2018.20045 · Cited by 703 · cited 1×
“showing that reductions in triglyceride levels do not reduce CVD risk unless there was an accompanying reduction in circulating apoB levels, and that the reduction in risk was proportional to the decrement in apoB (105).”
BackgroundSelf-citation
Overproduction of large VLDL particles is driven by increased liver fat content in man
Adiels, M., Taskinen, M.-R., Packard, C., Caslake, M. J., Soro-Paavonen, A., Westerbacka, J., Vehkavaara, S., Häkkinen, A., Olofsson, S.-O., Yki-Järvinen, H., et al. (2006) · Diabetologia · doi:10.1007/s00125-005-0125-z · Cited by 690
Self-citation
A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection
Pollin, T. I., Damcott, C. M., Shen, H., Ott, S. H., Shelton, J., Horenstein, R. B., Post, W., McLenithan, J. C., Bielak, L. F., Peyser, P. A., et al. (2008) · Science · doi:10.1126/science.1161524 · Cited by 688 · cited 1×
“Genetic studies have also shown that carriers of the APOC3 null mutation R19X have 50% lower plasma apoC-III levels, 35% lower plasma triglycerides, markedly lower postprandial triglycerides and significantly lower coronary artery calcification (CAC) scores than non-carriers (96, 97).”
Background

Flagged first, then by citations

Show all 149 references

Sorted by citations

Items 101–196 of 196

Apolipoprotein C-III in association with metabolic-dysfunction associated steatotic liver disease: A large, multicenter study
Kouvari, M., Valenzuela‐Vallejo, L., Guatibonza-García, V., Verrastro, O., Axarloglou, E., Mylonakis, S. C., George, J., Papatheodoridis, G., Mingrone, G., & Mantzoros, C. S. (2024) · Clinical Nutrition · doi:10.1016/j.clnu.2024.10.007 · Cited by 4
Characterisation of pregnancy-induced alterations in apolipoproteins and their associations with maternal metabolic risk factors and offspring birth outcomes: a preconception and longitudinal cohort study
Chen, L., Tan, K. M. L., Leow, M. K., Tan, K. H., Chan, J. K. Y., Chan, S., Chong, Y. S., Gluckman, P. D., Eriksson, J. G., Wenk, M. R., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105562 · Cited by 4
Complex dichotomous links of nonalcoholic fatty liver disease and inflammatory bowel disease: exploring risks, mechanisms, and management modalities
Aggarwal, K., Singh, B. P., Goel, A., Agrawal, D., Bansal, S., Kanagala, S. G., Anamika, F., Gupta, A., & Jain, R. (2024) · Intestinal Research · doi:10.5217/ir.2024.00001 · Cited by 4
Cellular uptake of CPX-351 by scavenger receptor class B type 1–mediated nonendocytic pathway
Araie, H., Hosono, N., & Yamauchi, T. (2024) · Experimental Hematology · doi:10.1016/j.exphem.2024.104651 · Cited by 4
Assessing the clinical potential of plozasiran, an APOC3 siRNA therapy for severe hypertriglyceridemia
Tang, X. L., Hooper, A. J., & Burnett, J. R. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2414126 · Cited by 4
“ApoC-III exerts its effects by several mechanisms, including inhibition of lipoprotein lipase (LPL) and hepatic lipase, increased TRL production, decreased hepatic TRL-remnant clearance, and modulating intestinal TG trafficking [2].”
Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies
Alam, U., Mathai, S. V., Filtz, A., Kuno, T., Badimon, J. J., Sniderman, A. D., Virani, S. S., Toth, P. P., Shapiro, M. D., Lavie, C. J., et al. (2026) · Current Cardiology Reports · doi:10.1007/s11886-025-02337-1 · Cited by 4
“…(LPL) and impairs hepatic rem - nant clearance—and angiopoietin-like proteins (ANG-PTL3/4/8)—which modulate LPL activity in fed versus fasting states—along with genetic factors and insulin resistance, play a critical role in determining triglyceride-rich lipoprotein (TRL) metabolism [ 13, 15–17 ].”
Icosapent ethyl–induced lipoprotein remodeling and its impact on cardiovascular disease risk markers in normolipidemic individuals
Äikäs, L., Kovanen, P. T., Lorey, M. B., Laaksonen, R., Holopainen, M., Ruhanen, H., Käkelä, R., Jauhiainen, M., Hermansson, M., & Öörni, K. (2025) · JCI Insight · doi:10.1172/jci.insight.193637 · Cited by 5
“Previous studies have suggested increased LPL activity after n-3 supplementation (39–41), partly due to reduced apoC-III (42); however, the mechanism by which IPE impacts ANGPTL3 remain unknown.”
Use of plozasiran across a spectrum of hypertriglyceridemia: Long-term efficacy and safety data from the open-label extension period of SHASTA-2 and MUIR Trials
Ballantyne, C. M., Baass, A. W., Rosenson, R. S., Hegele, R. A., Nicholls, S. J., Vasas, S., Clifton, P. M., Lucas, K. J., Páll, D., Zhou, R., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101523 · Cited by 3
APOC3 Promotes DGAT2-Dependent Triglyceride Accumulation in Hepatocytes During Early Metabolic Dysfunction
Nguyen, T. N., Kim, H.-J., Shim, H. M., Kang, J., Ha, E. Y., Cho, H., & Park, J. (2026) · Biomolecules · doi:10.3390/biom16040607 · Cited by 3
“During the development of insulin resistance, however, this inhibitory effect may become attenuated, allowing APOC3 expression to increase despite elevated insulin levels [17].”
Influential
Proteomic analysis emphasizes the adaptation of energy metabolism in horses during endurance races
Gotić, J., Špelić, L., Kuleš, J., Horvatić, A., Gelemanović, A., Ljubić, B. B., Mrljak, V., & Bottegaro, N. B. (2025) · BMC Veterinary Research · doi:10.1186/s12917-025-04518-0 · Cited by 3
Breakfast partly restores the anti-inflammatory function of high-density lipoproteins from patients with type 2 diabetes mellitus
Lemmers, R. F. H., Martens, N., Maas, A. H., der Zee, L. C. V. V., Leijten, F. P. J., Ruijven, C. M. G.-V., van Hoek, M., Lieverse, A. G., Sijbrands, E. J. G., Haak, H. R., et al. (2021) · Atherosclerosis Plus · doi:10.1016/j.athplu.2021.08.006 · Cited by 3
“We did not observe a meal-induced change in the relative apoC-II þ apoC-III content of HDL, which may suggest that HDL-bound apoC-II is displaced by apoC-III [35].”
Background
Systematic Assessment of Protein C-Termini Mutated in Human Disorders
FitzHugh, Z. T., & Schiller, M. R. (2023) · Biomolecules · doi:10.3390/biom13020355 · Cited by 3
“Elevated bloodstream APOC-III is associated with cardiovascular diseases, hypertriglyceridemia, and diabetes [72,73].”
Background
Apoliprotein C-III (Apo C-III) inhibitors effect of antisense oligonucleotides in the management of dyslipidemia
Sasmana, I. G. A. P., Rahadi, P. N. K., Devy, A. A. T., Dewi, P. A. S., Supadmanaba, I. G. P., & Wihandani, D. M. (2023) · Indonesia Journal of Biomedical Science · doi:10.15562/ijbs.v17i1.455 · Cited by 3
Multiplexed assays of human disease-relevant mutations reveal UTR dinucleotide composition as a major determinant of RNA stability
Su, J.-Y., Wang, Y.-L., Hsieh, Y.-T., Chang, Y.-C., Yang, C., Kang, Y., Huang, Y., & Lin, C. (2025) · eLife · doi:10.7554/elife.97682.3 · Cited by 2
Triglyceride-independent associations between circulating levels of apolipoprotein C-III and biomarkers of inflammation
Llop, D., Rehues, P., Paredes, S., Guardiola, M., Girona, J., Rosales, R., Esteban, Y., Masana, L., Ibarretxe, D., Vallvé, J.-C., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02553-z · Cited by 2
Lessons from recent clinical trials for the prevention of acute pancreatitis in chylomicronemia syndromes
D’Erasmo, L., Tramontano, D., & Arca, M. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000941 · Cited by 2
Dysapolipoproteinaemia Influences the Relationship Between Very Low-Density Lipoprotein Cholesterol and Intra-Pancreatic Fat Deposition in Humans
Liu, Y., Skudder‐Hill, L., Ko, J., Shamaitijiang, X., Sequeira, I. R., & Petrov, M. S. (2025) · Nutrients · doi:10.3390/nu17233718 · Cited by 2
“Additionally, both apo C-II and apo C-III play key roles in VLDL metabolism [24–26].”
Efficacy and Safety of Olezarsen in Hypertriglyceridemia: An Updated Meta‐Analysis of Randomised Controlled Trials
Emara, A., Mansour, A., Aboeldahab, H. A., Awashra, A., Abbas, O. F., Abdul‐Hafez, H. A., Alsubaiei, A. A., AlSejari, N., Saif, H. S., Shubietah, A. R. M., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70716 · Cited by 2
Lipid dysregulation in chronic diseases: systems biology and omics perspectives
Majumder, D., Bhattacharya, D., Gill, H. S., Rajeev, M., Sharma, S., Dwivedi, S. P., Nag, M., & Lahiri, D. (2026) · Xenobiotica · doi:10.1080/00498254.2026.2680076 · Cited by 2
“Similarly, alterations in apoc-iii composition on triglyceride-rich lipoproteins are predictive of hypertriglyceridaemia and atherosclerosis (Borén et al. 2020). in this way, proteomics provides mechanistic information and candidate biomarkers for lipid diseases.”
Targeting Apolipoprotein C-III for the Management of Severe Hypertriglyceridemia: Current Research and Future Directions
Shah, M. A., Sharma, A., Ayyad, M., Swartz, E., Jafrani, D., & Gala, D. (2024) · Cureus · doi:10.7759/cureus.67091 · Cited by 2
“Mainly produced in the liver with some contribution from the intestines, APOC3 is found in very low-density lipoproteins (VLDLs) and high-density lipoproteins (HDLs) [4].”
Background
Potential of CETP inhibition in treating dyslipidemia in systemic lupus erythematosus: Novel and comprehensive evidence from clinical studies and Mendelian randomization
Gan, Y., Zhang, Y., Liu, J., Jin, M., Lin, K., Chen, S., Jiang, C., Mao, Y., Xie, G., Bao, J., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114736 · Cited by 2
Subpopulations of High-Density Lipoprotein: Friends or Foes in Cardiovascular Disease Risk in Chronic Kidney Disease?
Coimbra, S., Reis, F., Valente, M. J., Rocha, S., Catarino, C., Rocha‐Pereira, P., Faria, M., Bronze-da-Rocha, E., Belo, L., & Santos‐Silva, A. (2021) · Biomedicines · doi:10.3390/biomedicines9050554 · Cited by 2
Familial chylomicronemia syndrome due to a heterozygous deletion of the chromosome 8 treated with the apoCIII inhibitor volanesorsen
Tünnemann-Tarr, A., Scharnagl, H., Katzmann, J. L., Stürzebecher, P. E., & Laufs, U. (2021) · Medicine · doi:10.1097/md.0000000000027573 · Cited by 2
“ApoCIII inhibits LPL activity, reduces the hepatic uptake of triglyceride-rich lipoproteins and increases hepatic secretion of triglycerides.([17]) Loss-of-function (LOF) mutations of the gene coding for apoCIII and pharmacologic inhibition of apoCIII lead to reduced plasma triglyceride levels.”
Lipids, Lipoproteins, and Cardiovascular Outcomes
Sakers, A. P., Mszar, R., & Soffer, D. E. (2024) · Contemporary cardiology · doi:10.1007/978-3-031-54960-1_9 · Cited by 1
ApoJ and apoL1 as novel determinants of MASH: a cross-sectional study
Cai, Z., Najib, S., Núñez‐Sánchez, M. Á., Martínez‐Sánchez, M. A., García-Melgares, C., Viguerie, N., Rossell, J., Julve, J., Croyal, M., Oliveira, A. R., et al. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02733-0 · Cited by 1
Effect of a polyphenol-rich extract on LDL cholesterol in mild to moderate hypercholesterolemia: a randomized, double-blind, placebo-controlled trial
Sirvent, P., Langhi, C., Vallier, M., Oliveira, A. R., Croyal, M., Otero, Y. F., Chavanelle, V., Michaux, A., Bargetto, M., Joubioux, F. L., et al. (2025) · European Journal of Clinical Nutrition · doi:10.1038/s41430-025-01691-1 · Cited by 1
Reduced postprandial lipid accumulation in circulating monocytes by olezarsen attenuates pro-inflammatory changes in hypertriglyceridemic patients
Peletier, M. C., Kraaijenhof, J. M., Versloot, M., Koppejan, H., Dzobo, K. E., Alexander, V. J., Tsimikas, S., Stroes, E. S. G., & Kroon, J. (2026) · European Heart Journal Open · doi:10.1093/ehjopen/oeag025 · Cited by 1
“14 Recently, Peng and colleagues elucidated the direct link between apoC-III and atherosclerotic plaque development in mice, supporting the preclinical antiatherogenic potential of apoC-III-induced TG lowering.”
The evaluation of plozasiran for the treatment of familial chylomicronemia syndrome
Hang, S., & Hegele, R. A. (2026) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2026.2646166 · Cited by 2
“…been proposed that apo C-III promotes the synthesis and hepatic secretion of TG-rich lipoproteins (TRLs), inhibits LPL-mediated lipolysis, and impairs hepatic clearance of TRL remnants through LPL-independent pathways, potentially by interfering with binding to hepatic receptors (Figure 1) [36].”
Lipid-lowering and glucose-lowering drug targets differentially modulate antipsychotic treatment efficacy in schizophrenia
Zhu, Y., Yuan, R., Lu, Z., Zhang, Y., Kang, Z., Feng, X., Zhao, G., Sun, J., Guo, J., Yu, T., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102653 · Cited by 1
ANGPTL3, Apo CIII, Leptin and Triglycerides Are Elevated in Metastatic Prostate Cancer
Boulay, G., Khodr, M., Bergeron, A.-C., Chong, E. W., Joncas, F., Castonguay, C., Robitaille, K., Hovington, H., Fradet, V., Bergeron, A., et al. (2026) · Cancers · doi:10.3390/cancers18071176 · Cited by 1
“Apo CIII also negatively regulates Apo E-mediated hepatic uptake of TRLs and lipoprotein remnants via the LDL receptor (LDLR) and LDLR-related protein 1 (LRP1) [32–34].”
Production and Metabolism of Triglyceride-Rich Lipoproteins: Impact of Diabetes
Pirillo, A., Norata, G. D., & Catapano, A. L. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_7 · Cited by 3
Low-Density Lipoprotein Cholesterol Is Not a Major Determinant of High-Sensitivity C-Reactive Protein Levels in People Without Known Diabetes Mellitus
Su, G.-Y., Ning, N. X., Lin, K., & Hwu, C. (2023) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2023.0061 · Cited by 1
“25,26 Insulin resistance is also associated with increased activity of hepatic TG lipase, which enhances the fractional catabolic rate of HDL, hence low serum HDL-C, and facilitates the generation of small dense LDL. 25 The excess intrahepatic lipid accumulation promotes lipid peroxidation and increased oxidative stre…”
Contractile and Genetic Characterization of Cardiac Constructs Engineered from Human Induced Pluripotent Stem Cells: Modeling of Tuberous Sclerosis Complex and the Effects of Rapamycin
Sidorov, V. Y., Sidorova, T. N., Samson, P. C., Reiserer, R. S., Britt, C. M., Neely, M. D., Ess, K. C., & Wikswo, J. P. (2024) · Bioengineering · doi:10.3390/bioengineering11030234 · Cited by 1
The Evaluation of Lipid Analysis for PXB-Cells LA as a Human Non-Alcoholic Fatty Liver Disease Model
Takahashi, M., Tomatsu, S., Inamatsu, M., Yoshikawa, N., Hata, K., & Kakuni, M. (2024) · BPB Reports · doi:10.1248/bpbreports.7.4_147 · Cited by 1
Multiplexed Assays of Human Disease-relevant Mutations Reveal UTR Dinucleotide Composition as a Major Determinant of RNA StabilityPreprint
Su, J.-Y., Wang, Y.-L., Hsieh, Y.-T., Chang, Y.-C., Yang, C., Kang, Y., Huang, Y., & Lin, C. (2024) · eLife · doi:10.7554/elife.97682.1 · Cited by 1
Systemic inflammation is a minor contributor to remnant cholesterol atherogenicityPreprint
Kraaijenhof, J. M., Kerkvliet, M., Nurmohamed, N. S., Grefhorst, A., Kroon, J., Wareham, N. J., Hovingh, G. K., Stroes, E. S. G., Boekholdt, S. M., & Reeskamp, L. F. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.18.604203 · Cited by 1
Remodelling of plasma lipoproteins by icosapent ethyl -supplementation and its impact on cardiovascular disease risk markers in normolipidemic individualsPreprint
Äikäs, L., Kovanen, P. T., Lorey, M. B., Laaksonen, R., Holopainen, M., Ruhanen, H., Käkelä, R., Jauhiainen, M., Hermansson, M., & Öörni, K. (2024) · medRxiv · doi:10.1101/2024.11.27.24318042 · Cited by 1
Multiplexed Assays of Human Disease-relevant Mutations Reveal UTR Dinucleotide Composition as a Major Determinant of RNA StabilityPreprint
Su, J.-Y., Wang, Y.-L., Hsieh, Y.-T., Chang, Y.-C., Yang, C., Kang, Y., Huang, Y., & Lin, C. (2025) · eLife · doi:10.7554/elife.97682.2 · Cited by 1
Targeting triglycerides for cardiovascular risk reduction
Maiorca, C., Tramontano, D., Di Costanzo, A., & D’Erasmo, L. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04383-1
“Indeed, beyond its inhibitory action on lipoprotein lipase (LPL), apoC-III also delays hepatic uptake of TRL remnants, contributing to both hypertriglyceridemia and atherosclerotic progression through LPL-independent pathways [111].”
Lipoproteins in the postprandial state: Studies on the metabolism of triglyceride-rich lipoproteins using multicompartmental models
Björnson, E. (2021) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Primär genetische Dyslipoproteinämien und Atheroskleroserisiko
Schwab, K. O., & Doerfer, J. (2022) · Springer eBooks · doi:10.1007/978-3-662-63320-5_3
Biomarkers in Disease: Diabetes Methods, Discoveries and Applications
de Carvalho, L. S. F., Asari, A. I. A., Teles, B. S. B. D. S., Chaves‐Filho, A. B., & Yoshinaga, M. Y. (2022) · Biomarkers in disease · doi:10.1007/978-3-030-81303-1_20-1
Biomarkers in Disease: Diabetes Methods, Discoveries, and Applications
de Carvalho, L. S. F., Asari, A. I. A., Teles, B. S. B. D. S., Filho, A. D. B. C., & Yoshinaga, M. Y. (2022) · Biomarkers in disease · doi:10.1007/978-3-031-08014-2_20
Effects of Liraglutide on Glycemic Control and Lipid Profile in Obese Type 2 Diabetes Mellitus Iraqi Patients
Abdulrahman, A. J., AL-Zobaidy, M. A.-H. J., & Najjar, S. A. (2022) · The Egyptian Journal of Hospital Medicine · doi:10.21608/ejhm.2022.266014
“Since ApoCIII reduces lipoprotein lipase activity and prevents receptor-mediated absorption of TG-rich lipoproteins, TG-rich lipoproteins take longer to be cleared from the body((18)).”
Background
Targeting sedentary behaviour
Franssen, W. M. A. (2022) · Research Publications (Maastricht University) · doi:10.26481/dis.20221121wf · Cited by 1
Lipoproteins and Diabetic Kidney Disease
Sigfrids, F. J., Elonen, N., & Groop, P. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_15
Fibrate Therapy: Impact on Dyslipidemia and Cardiovascular Events in Patients with Diabetes Mellitus Type 2
Brinton, E. A., & Pulipati, V. P. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_24
Serum triacylglycerol: A putative early biomarker of disease severity of Type 2 diabetes mellitus compared to microalbuminuria
Saha, T., Sarma, N., Dawn, S., Dhar, A., Chatterjee, N., Hadem, I. K. H., Hazra, A., Pal, A., Sahoo, S., Dutta, A. K., et al. (2023) · Indian Journal of Experimental Biology · doi:10.56042/ijeb.v61i07.2214
Integrative Analysis of the Blood Proteome by Mendelian Randomization Reveals Regulatory Networks in Calcific Aortic Valve DiseasePreprint
Briend, M., Moncla, L.-H. M., Duclos, V., Mathieu, S., Rufiange, A., Thériault, S., Arsenault, B. J., Bossé, Y., & Mathieu, P. (2023) · medRxiv · doi:10.1101/2023.07.26.23293222
Subfractions of Low-Density-Lipoprotein: Which is the Most Atherogenic?
Poznyak, A. V., Sukhorukov, V. N., Popov, M. A., Grechko, A. V., & Orekhov, A. N. (2023) · OnLine Journal of Biological Sciences · doi:10.3844/ojbsci.2023.432.440
“This pool of data provides exhaustive evidence of the causal role of LDL in atherogenesis (Borén et al., 2020).”
Background
RNA interference-based therapies for atherosclerosis: Recent advances and future prospects
Parsamanesh, N., Poudineh, M., Siami, H., Butler, A. E., Almahmeed, W. A., & Sahebkar, A. (2023) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2023.12.009 · Cited by 1
Further Reading
Kontush, A. (2024) · doi:10.1002/9781394158393.ch21b
Familial combined hyperlipidemia: current status of the problem (literature review)
Тимощенко, О. В., & Шахтшнейдер, Е. В. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-5874
Apolipoprotein CIII correlates with lipoproteins in the fed state and is not regulated by leptin administration in states of hypoleptinemia induced by acute or chronic energy deficiency: Results from two randomised controlled trials
Ramirez‐Cisneros, A., Stefanakis, K., & Mantzoros, C. S. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16194
“In particular, nutritional intake triggers shifts in circulating lipoprotein profiles, including the modulation of APOC3 38 which are tightly linked to energy states, with fed conditions markedly contrasting the adaptations seen during fasting or energy deprivation.”
Characterization of metabolically healthy and unhealthy obesity through circulating proteins and metabolitesPreprint
Pontali, G., Weichenberger, C. X., Rainer, J., Hantikainen, E. M., Graeve, M. D., Mattivi, F., Kob, M., Ralser, M., Pramstaller, P. P., & Domingues, F. S. (2025) · medRxiv · doi:10.1101/2025.03.10.25323679
“The protein is a therapeutic target of volanesorsen, a drug approved for reduction of triglyceride levels, and is a candidate target for reducing CVD risk [49, 59].”
Quantitative proteomic analysis of the protective effect exerted by alliin on ox-LDL-injured HUVECs
Tang, Y., & Lv, D. (2025) · Scientific Reports · doi:10.1038/s41598-025-01677-w
“Up-regulation of ApoC expression has been shown to increase lipoprotein lipase activity and promote the clearance of triglyceride-rich lipoproteins 39 .”
Modeling the postprandial CETP-mediated lipid redistribution between chylomicrons, LDL and HDL
Jansen, M., Contini, C., Hoffmann, M. M., & Pütz, G. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100847
Exploring the relationship between lipid-lowering drug target genes and sensorineural hearing loss by Mendelian randomization
Yang, Y., Huang, H.-F., & Pu, K. (2025) · Medicine · doi:10.1097/md.0000000000044174
“[33] Human knock-out studies of ApoC3 have shown that ApoC3 deficiency lowers plasma triglyceride and cholesterol levels and increases HDL-C levels.”
Molecular and cellular targets in the management of metabolic diseases and disorders: An overview
Cariño‐Cortés, R., Isabel, S.-C. M., Antonio, E.-D. J., Luis, J.-S., Fernández‐Martínez, E., & Fernanda, V.-C. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27370-4.00004-4
Pharmacological targets in metabolic syndrome related dyslipidemia
Cariño‐Cortés, R., Manuel, M.-P. V., Ortiz, M. I., Luis, J.-S., Fernández‐Martínez, E., & Fernanda, V.-C. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27370-4.00005-6
Olezarsen: A Next-Generation Antisense Therapy for Hypertriglyceridemia and Familial Chylomicronemia Syndrome
Joshy, J., Javed, A., Singh, M. K., Singh, B., Kumar, R., & Hussain, S. (2025) · Cureus · doi:10.7759/cureus.96715 · Cited by 1
“This means that even in patients with a defective LPL enzyme, triglycerides can still be metabolized [24,29,30].”
Additional file 1 of ApoC3 is expressed in oocytes and increased expression is associated with PCOS progression
Zhou, J., Mo, H., Feng, Q., Li, L., & La, J. (2024) · Figshare · doi:10.6084/m9.figshare.26616385
Efficacy and Safety of Olezarsen in Patients With Hypertriglyceridemia: A Meta‐Analysis of Randomized Controlled Trials
Feroz, K., Parvez, A., Ramzan, N. U. H., Asghar, T., Cheema, A. H., Malik, A. P., Fatima, T., Iqbal, J., & Sathian, B. (2026) · Cardiovascular Therapeutics · doi:10.1155/cdr/9984822
Pathogenesis of type 2 diabetes
Honka, M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00376-9
Changes in apolipoproteins following ingestion of a beverage delivering β-hydroxybutyrate: results from a randomized placebo-controlled trial
Liu, Y., Kimita, W., Bharmal, S. H., & Petrov, M. S. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1726174
“By contrast, apo C-III has an inhibitory effect on LPL, leading to reduced lipolysis of TRL particles and reduced clearance of TRL remnants (21).”
Efficacy and safety of antisense oligonucleotide therapies targeting APoC-III in patients with severe hypertriglyceridemia: a meta-analysis of randomized controlled trials
Masood, A., Qureshi, A. U. H., Khalid, Z., Shahid, H., Malik, A. R. K., Javed, S., Mandahar, M., Amanullah, A., Siddiqui, Y., Anwar, T., et al. (2026) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2026.3543
Feasibility of remnant cholesterol as a therapeutic target for atherosclerotic cardio-vascular disease
Wulff, A. B., Varbo, A., Nordestgaard, A. G., & Nordestgaard, B. G. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2639678 · Cited by 2
Chardonnay grape marc/grape seed extract blends improve postprandial triglycerides and/or HDL cholesterol concentrations in adults with mild dyslipidemia in a randomized double blinded crossover trial
Lee, F., Arvik, T. J., Newman, J. W. I., & Keim, N. L. (2026) · Nutrition Research · doi:10.1016/j.nutres.2026.02.009
Integrative phytochemical profiling and in silico nutrigenomic predictions of Chinese tea–Saudi Mentha longifolia blend formulations
Fallatah, T. A., Abdelmigid, H. M., Alyamani, A. A., Morsi, M. M., Ali, M., Lu, J., Zhao, J., & Heikal, Y. M. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1753616
High cholesterol absorption efficiency enhances proatherogenic properties of low‐density lipoprotein particles
Öörni, K., Äikäs, L., Ruuth, M. K., Tigistu‐Sahle, F., Käkelä, R., Wester, I., Gylling, H., & Simonen, P. P. (2026) · Journal of Internal Medicine · doi:10.1111/joim.70085
“CETP facilitates the exchange of TGs from VLDL to LDL and HDL, effectively enriching these particles with TGs that are subsequently hydrolyzed by hepatic lipase, reducing the size of the LDL and HDL [45].”
Clinical identification of familial chylomicronemia syndrome and novel therapeutic options
Hang, S., & Hegele, R. A. (2026) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2026.2661212
“Apo C-III is a 79–amino acid, helix-forming glycoprotein synthesized predominantly by hepatocytes and enterocytes [51].”
Emerging insights into PPARα′s role in lean metabolic dysfunction-associated steatotic liver disease: Implications for targeted therapies
Yang, Y., Zhang, F., Peng, Z., Wu, Y., Li, L., Shen, Z., Ye, Q., Yue, J., & Na, S. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.06.029
Association of frailty and metabolism with multi-state model in fatty liver disease, diabetes mellitus and all-cause mortality
暁燕, 王., Jin, C., Zhong, Q., Wang, X., Xu, Y., Li, M., Liu, L., Huang, H., 梁安莹, Wang, J., et al. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02201-4
“Visceral adipose dysfunction impairs insulin sensitivity [26], while dyslipidemia (elevated TG, low HDL) exacerbates β-cell apoptosis [27], explaining the 5-fold higher NIDDM risk in MetS individuals [28].”
Quels traitements médicamenteux en 2025 pour réduire le risque cardiovasculaire associé à l’hypertriglycéridémie ?
Mourre, F., & Béliard, S. (2026) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2026.05.002
Clinical Pharmacology of Plozasiran
Huston, J., Orey, D., Corona, K., Ashchi, A., Ashchi, A., Deeb, E., Deeb, A., Rouhbakhsh, R., Berner, J., Sutton, D., et al. (2026) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-026-00808-6
“This dual mechanism is why targeting apoC-III can effectively lower triglycerides in patients with FCS, even when LPL is severely impaired or absent [9–11].”
Linking Lipidomics to Vulnerable Coronary Plaques: A PROSPECT II Substudy
Sharma, T., Fall, T., Sayols-Baixeras, S., Maehara, A., Mæng, M., Kjøller‐Hansen, L., Engstrøm, T., Ben‐Yehuda, O., Matsumura, M., Fröbert, O., et al. (2026) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.125.324430
Self-citation
Apolipoprotein E's impact on metabolic syndrome: A systematic analysis
Sania, A., Bajad, N. G., Lari, M. Q., & Ganeshpurkar, A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-40563-1.00005-3
Silencing Triglycerides: The Clinical Impact of Plozasiran and apoC-III Inhibition in Severe Hypertriglyceridemia
Kassem, B. A., Shaik, F. A., Sorour, O., Abdelhamid, A. H., Fazal, A., Dakroub, A. H., & Eid, A. H. (2026) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001846
Genetic variants associated with triglyceride metabolism and fasting triglyceride concentrations: a systematic review and a meta-analysis
Nuwaylati, D. A., Mensink, R. P., Joris, P. J., Coort, S. L., & Plat, J. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.06.019
siRNA-Mediated Reduction of Apolipoprotein CIII Delays Pancreatic Islet Deterioration and Onset of Type 1 Diabetes in Diabetes-Prone BioBreeding Rats
Recio-López, P., Rehues, P., Berggren, P., Juntti‐Berggren, L., & Valladolid‐Acebes, I. (2026) · Biomedicines · doi:10.3390/biomedicines14071481
Exploratory whole-exome analysis of low-density lipoprotein cholesterol and triglyceride response to Mediterranean-style dietary guidance: a focus on plasma lipoprotein pathways
Iordanishvili, S., Chiradze, N., Agladze, D., Kikvidze, M., Khuchua, Z. A., Lagani, V., & Solomonia, R. O. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1827989
Integrative exome sequencing and multi-omics analysis elucidates the regulatory role of rare variants in metabolic syndrome
Wu, C., Sang, J., Xu, Q., Zhan, Y., Yuan, S.-J., Ge, Y.-Y., Yu, X.-J., Zheng, X., Wang, X.-F., He, X.-M., et al. (2026) · Functional & Integrative Genomics · doi:10.1007/s10142-026-01987-w
“…levels by inhibiting lipoprotein lipase activity and interferes with the hepatic clearance of triglyceride-rich lipoproteins and their remnants by disrupting the function of low-density lipoprotein receptors and lipoprotein receptor-related protein 1 (Borén et al. 2020, Hsu et al. 2023).”
Carbohydrates and Lipids
Minden, A. (2026) · Springer eBooks · doi:10.1007/978-3-032-20529-2_9
Lipids and apolipoproteins affect the risk of ST-elevation and non-ST-elevation myocardial infarctions differently in type 1 diabetes: a nationwide finnish cohort study
Smidtslund, P., Sigfrids, F. J., Harjutsalo, V., Thorn, V., Taskinen, M., Groop, P., Thorn, L. M., & FinnDiane Study Group (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03315-9
“ApoC-III is a noteworthy apolipoprotein in type 1 diabetes, since its levels are independently influenced by insulin and glucose, and it is an important regulator of triglyceride transport [28, 29].”
Self-citation
Single-dose ION775, a GalNAc-conjugated siRNA targeting APOC3, lowers triglycerides for up to 12 months in moderate hypertriglyceridemia
Tsimikas, S., Morgan, E. S., Sharma, J., Lin, T., Mullick, A. E., Prakash, T. P., Swayze, E. E., & Prohaska, T. A. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.08.012
Characterization of metabolically healthy and unhealthy obesity by circulating omics
Pontali, G., Weichenberger, C. X., Rainer, J., Hantikainen, E. M., Graeve, M. D., Mattivi, F., Kob, M., Ralser, M., Pramstaller, P. P., & Domingues, F. S. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104998
Remnant clearance capacity: a new framework for early type 2 diabetes pathogenesis
Nakajima, K., Murakami, M., & Tanaka, A. (2026) · Clinica Chimica Acta · doi:10.1016/j.cca.2026.121345
VLDL Phospholipid Composition, Remnant Cholesterol, ApoB , and Coronary Artery Disease: A Network Mendelian Randomization Study
Yu, H., Zhang, X., Yang, S., Fan, Z., Zhang, D., & Dan, W. A. N. G. (2026) · Lipids · doi:10.1002/lipd.70085
Early Hepatic Transcriptomic Responses to High-Fat Diet in Apolipoprotein A-IV Knockout Mice
Żeber-Lubecka, N., Kulecka, M., Pyśniak, K., Dąbrowska, M., & Hennig, E. E. (2026) · Metabolites · doi:10.3390/metabo16090695
“…that reduced ApoC3 expression would favor triglyceride clearance, ApoA-IV-deficient mice displayed elevated circulating triglyceride levels under HFD, suggesting that ApoA-IV deficiency affects additional pathways involved in triglyceride homeostasis beyond ApoC3-dependent regulation [44].”
Canonical and Non-Canonical Regulators of Lipid Metabolism in the Liver and the “Liver–Other Organs” Axes
Kotlyarov, S. N., Котлярова, А. А., Catanzaro, R., & Marotta, F. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27198614
Olezarsen for the Treatment of Hypertriglyceridemia
Rodriguez, A. S. H., & Yokota, T. (2026) · Methods in molecular biology · doi:10.1007/978-1-0716-5476-7_6
Apolipoprotein CIII as a therapeutic target in obesity-associated metabolic dysfunction
Valladolid‐Acebes, I., Berggren, P., & Juntti‐Berggren, L. (2026) · Advances in Biological Regulation · doi:10.1016/j.jbior.2026.101183
Residual Atherogenic Dyslipidemia in Normal-Weight Adults: The Role of Visceral Adiposity and Metabolic Dysfunction
Carrasco, D. G., López, P. J. T., Piña-D’Abreu, M., Cañellas, L. R., López‐González, Á. A., & Ramírez‐Manent, J. I. (2026) · Medical Sciences · doi:10.3390/medsci14060655
“Previous investigations have demonstrated that triglyceride-rich lipoproteins and remnant cholesterol particles contribute significantly to residual cardiovascular risk independently of LDL cholesterol concentrations [71,72].”
Mechanisms of Hepatic Insulin Resistance and Its Contribution to the Pathogenesis of Type 2 Diabetes
Onyango, A. N. (2026) · Comprehensive physiology · doi:10.1002/cph4.70285
“In vitro, ApoC3-enriched VLDL was shown to reduce skeletal muscle glucose uptake by binding to myocyte TLR2, leading to ER stress and AMPK inhibition (Botteri et al. 2017).”
Influential
Persistent atherogenic lipoprotein changes during lorlatinib therapy
Shibue, K., Kunimasa, K., & Hamasaki, A. (2026) · JCEM Case Reports · doi:10.1210/jcemcr/luag324
“Apolipoprotein C-III is an important regulator of triglyceride-rich lipoprotein metabolism through inhibition of lipoprotein lipase activity and reduced hepatic clearance of triglyceride-rich lipoproteins and their remnants [12].”
Inhibiting apolipoprotein C3 alleviates ferroptosis and cell damage induced by Pseudomonas aeruginosa
Yaoyang, L. I. U., Yang, X., 倪天纯, 宗家录, Qian, C., Wang, X., & Yu, J. (2026) · Microbial Pathogenesis · doi:10.1016/j.micpath.2026.108872

Authors: Borén, J., Packard, C. J., & Taskinen, M.-R.
Affiliations: University of Gothenburg (SE)
University of Glasgow (GB)
University of Helsinki (FI)
Corresponding author: Borén, Jan
ORCID: Borén, Jan
Packard, Chris J.
Taskinen, Marja-Riitta
Venue: Frontiers in Endocrinology
Publisher: Frontiers Media SA
Published: 2020-07-28
Volume: 11
Pages: 474-474
ISSN: 1664-2392 (ISSN-L)
DOI: 10.3389/fendo.2020.00474
PMC: PMC7399058
OpenAlex: W3045911834
Cited by: 196
References: 149
Citations by year: 2026: 46 · 2025: 35 · 2024: 30 · 2023: 32 · 2022: 35 · 2021: 17 · 2020: 1
FWCI: 3.61
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0/ (vor)
Locations: Frontiers in Endocrinology (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Työväentutkimus Vuosikirja (submittedVersion)
Funders: Vetenskapsrådet
Hjärt-Lungfonden
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords: apolipoprotein C-III, triglyceride-rich lipoproteins, triglyceride metabolism, cardiovascular disease, dyslipidemia, plasma triglycerides, atherogenic lipoproteins, triglyceride transport, obesity, insulin resistance
MeSH terms: Cardiovascular Diseases, Humans, Lipoproteins, Triglycerides, Atherosclerosis, Lipid Metabolism, Apolipoprotein C-III

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks